Firebrick Pharma Limited ( (AU:FRE) ) has shared an announcement.
Firebrick Pharma Limited reported its financial results for the half-year ending December 31, 2024, showing a revenue increase to $196,752, up from zero in the previous period. Despite the revenue growth, the company faced a significant increase in losses, with a 60.99% rise in loss after tax to $1,446,378. No dividends were declared, and the auditor’s report highlighted a material uncertainty regarding the company’s ability to continue as a going concern.
More about Firebrick Pharma Limited
Firebrick Pharma Limited operates in the pharmaceutical industry, focusing on the development and commercialization of health-related products and services, primarily targeting the Australian market.
YTD Price Performance: 38.33%
Average Trading Volume: 145,791
Technical Sentiment Consensus Rating: Sell
Find detailed analytics on FRE stock on TipRanks’ Stock Analysis page.